A5037277634- Bacterial Infections and Vaccines
- COVID-19 Clinical Research Studies
- Infectious Encephalopathies and Encephalitis
- Pneumonia and Respiratory Infections
- SARS-CoV-2 and COVID-19 Research
- Infectious Diseases and Tuberculosis
- Peripheral Neuropathies and Disorders
- Cerebrospinal fluid and hydrocephalus
- Long-Term Effects of COVID-19
- SARS-CoV-2 detection and testing
- Botulinum Toxin and Related Neurological Disorders
- Antifungal resistance and susceptibility
- Autoimmune Neurological Disorders and Treatments
- Herpesvirus Infections and Treatments
- COVID-19 and healthcare impacts
- Infective Endocarditis Diagnosis and Management
- Wound Healing and Treatments
- Diphtheria, Corynebacterium, and Tetanus
- Fungal Infections and Studies
- Orthopedic Infections and Treatments
- Systemic Lupus Erythematosus Research
- Head and Neck Surgical Oncology
- Healthcare cost, quality, practices
- Biosensors and Analytical Detection
- Antibiotic Use and Resistance
Methodist Hospital
2025
Methodist Hospital
2022-2024
Houston Methodist
2023-2024
Cleveland Clinic
2014-2023
Cleveland Clinic Lerner College of Medicine
2020
Case Western Reserve University
2020
Drexel University
2005
Abstract Background There are many pharmacologic therapies that being used or considered for treatment of coronavirus disease 2019 (COVID-19). is a need frequently updated practice guidelines on their use, based critical evaluation rapidly emerging literature. The objective was to develop evidence-based rapid intended support patients, clinicians, and other healthcare professionals in decisions about management patients with COVID-19. Methods Infectious Diseases Society America (IDSA) formed...
The Infectious Diseases Society of America (IDSA) Standards and Practice Guidelines Committee collaborated with partner organizations to convene a panel 10 experts on healthcare-associated ventriculitis meningitis. represented pediatric adult specialists in the field infectious diseases other whose members care for patients meningitis (American Academy Neurology, American Association Neurological Surgeons, Neurocritical Care Society). reviewed articles based literature reviews, review book...
Abstract IDSA Disclaimer As of the time this publication, updates have been made to IDSA’s Guidelines on Diagnosis COVID-19. For most updated version these guidelines, please go https://www.idsociety.org/covid19guidelines. Background Accurate molecular diagnostic tests are necessary for confirming a diagnosis coronavirus disease 2019 (COVID-19). Direct detection severe acute respiratory syndrome 2 (SARS-CoV-2) nucleic acids in tract specimens informs patient, healthcare institution, and...
BackgroundThe availability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic testing has rapidly increased. Current assays use a variety technologies, measure different classes immunoglobulin or combinations, and detect antibodies directed against portions the virus. The overall accuracy these tests, however, not been well defined. Infectious Diseases Society America (IDSA) convened an expert panel to perform systematic review disease 2019 (COVID-19) serology...
Abstract Background Accurate molecular diagnostic tests are necessary for confirming a diagnosis of coronavirus disease 2019 (COVID-19). Direct detection severe acute respiratory syndrome 2 (SARS-CoV-2) nucleic acids in tract specimens informs patient, healthcare institution and public health level decision-making. The numbers available SARS-CoV-2 acid rapidly increasing, as is the COVID-19 literature. Thus, Infectious Diseases Society America (IDSA) recognized significant need frequently...
Abstract There are many pharmacologic therapies that being used or considered for treatment of coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence from trials. The objective was to develop evidence-based, rapid, living guidelines intended support patients, clinicians, other healthcare professionals in their decisions about management patients COVID-19. In March 2020, the Infectious Diseases Society America (IDSA) formed a multidisciplinary guideline panel...
The role of serologic testing for SARS-CoV-2 has evolved during the pandemic as seroprevalence in global populations increased. Infectious Diseases Society America (IDSA) convened an expert panel to perform a systematic review coronavirus disease 2019 (COVID-19) serology literature and construct updated best practice guidance related testing. This guideline is update fourth series rapid, frequently COVID-19 guidelines developed by IDSA.
Abstract The Infectious Diseases Society of America (IDSA) Standards and Practice Guidelines Committee collaborated with partner organizations to convene a panel 10 experts on healthcare-associated ventriculitis meningitis. represented pediatric adult specialists in the field infectious diseases other whose members care for patients meningitis (American Academy Neurology, American Association Neurological Surgeons, Neurocritical Care Society). reviewed articles based literature reviews,...
The coronavirus disease of 2019 (COVID-19) emerged as a global pandemic. Historically, the group human coronaviruses can also affect central nervous system leading to neurological symptoms; however, causative mechanisms manifestations COVID-19 are not well known. Seizures have been directly reported part outside patients with previously known brain injury or epilepsy. We report two cases acute symptomatic seizures, in non-epileptic patients, associated severe disease.Two advanced-age,...
Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible virus that can infect healthcare personnel (HCP) and patients in settings. Specific care activities, particular, aerosol-generating procedures, may have higher risk of transmission. The rapid emergence global spread SARS-CoV-2 has created significant challenges facilities, particularly with severe shortages personal protective equipment (PPE) used to protect HCP. Evidence-based...
Cryptococcosis is increasingly recognized in people without human immunodeficiency virus (HIV).A multicenter, prospective cohort study was performed 25 US centers. Consenting patients were prospectively followed for ≤2 years. Neurological morbidities assessed with longitudinal event depiction and functional scores (Montreal Cognitive Assessment [MoCA]). Risks of death analyzed using Cox regression.One hundred forty-five subjects enrolled. Most male (95; 65.5%) had immunosuppression (120;...
Abstract Immunoassays designed to detect SARS-CoV-2 protein antigens are now commercially available. The most widely used tests rapid lateral flow assays that generate results in ~15 minutes for diagnosis at the point-of-care. Higher throughput, laboratory-based antigen (Ag) have also been developed. overall accuracy of Ag tests, however, is not well defined. Infectious Diseases Society America (IDSA) convened an expert panel perform a systematic review literature and develop best-practice...
Patients with COVID-19 have a fairly high risk of neurologic complications, including encephalopathy, stroke, central nervous system infection, seizures, and neuromuscular diseases. Many report losing their senses smell taste, many survivors lingering neurocognitive impairment. The diagnosis treatment these complications does not differ from that in other patients, although sophisticated testing may be readily available for patient intensive care respiratory isolation. Clinicians should...
Since its emergence in late 2019, SARS-CoV-2 continues to pose a risk healthcare personnel (HCP) and patients settings. Although all clinical interactions likely carry some of transmission, human actions like coughing care activities aerosol-generating procedures have higher transmission. The rapid global spread create significant challenges facilities, particularly with shortages personal protective equipment (PPE) used by HCP. Evidence-based recommendations for what PPE use conventional,...
Abstract Despite the challenges of pandemic, there has been substantial progress with coronavirus disease 2019 (COVID-19) therapies. Pivotal COVID-19 trials like SOLIDARITY, RECOVERY, and ACCT-1 were rapidly conducted data disseminated to support effective However, critical shortcomings remain on trial conduct, dissemination interpretation study results, regulatory guidance in pandemic settings. The lessons that we learned have implications for both current future emerging infectious...
2009 influenza A has spread globally. Respiratory complications and renal failure have been the leading causes for hospitalization critical illness. We describe risk factors of acute kidney injury (AKI) in patients with A.Observational study adult tested A. Outcome measures include AKI [AKI Network (AKIN) criteria] mortality.From August through December 2009, 17% (89/515) hospitalized subjects were positive The incidence (AKIN(I-III)) was 42% (37/89) A; majority (65%, 24/37) whom critically...
Abstract Accurate molecular diagnostic tests are necessary for confirming a diagnosis of coronavirus disease 2019 (COVID-19) and identifying asymptomatic carriage severe acute respiratory syndrome 2 (SARS-CoV-2). The number available SARS-CoV-2 nucleic acid detection continues to increase as does the COVID-19 literature. Thus, Infectious Diseases Society America (IDSA) developed an evidence-based guideline assist clinicians, clinical laboratorians, patients, policymakers in decisions related...